ArzneimittelPROFIL Venetoclax 2019

11. Literatur
In der Online-Version sind die Links zur PubMed-Datenbank, zu Kongressabstracts
sowie zum Studienregister verfügbar: www.arzneimittelprofil.at
Anderson MA, Huang D, & Roberts A: Targeting BCL2 for the treatment of
lymphoid malignancies; Semin Hematol 2014; 51: 219–227
https://www.ncbi.nlm.nih.gov/pubmed/25048785
Anderson MA, Deng J, Seymour JF, et al.: The BCL2 selective inhibitor
venetoclax induces rapid onset apoptosis of CLL cells in patients via a
TP53-independent mechanism; Blood 2016; 127: 3215–3224
https://www.ncbi.nlm.nih.gov/pubmed/27069256
Cimmino A, Calin GA, Fabbri M, et al.: miR-15 and miR-16 induce apoptosis
by targeting BCL2; Proc Natl Acad Sci USA 2005; 102: 13944–13949
https://www.ncbi.nlm.nih.gov/pubmed/16166262
Cory S, Roberts AW, Colman PM, et al.: Targeting BCL-2-like proteins to kill
cancer cells; Trends Cancer 2016; 2: 443–460
https://www.ncbi.nlm.nih.gov/pubmed/28741496
Coutre S, Choi M, Furman RR, et al.: Venetoclax for patients with chronic
lymphocytic leukemia who progressed during or after idelalisib therapy;
Blood 2018; 131: 1704–1711
https://www.ncbi.nlm.nih.gov/pubmed/29305552
Davids MS, Hallek M, Wierda W, et al.: Comprehensive safety analysis of
Venetoclax monotherapy for patients with relapsed/refractory chronic
lymphocytic leukemia; Clin Cancer Res 2018; 24: 4371–4379
https://www.ncbi.nlm.nih.gov/pubmed/29895707
Fachinformation Venetoclax (Venclyxto®); Stand 5.12.2018
https://www.ema.europa.eu/
Hallek M; German CLL Study Group: Prognostic factors in chronic
lymphocytic leukemia; Ann Oncol 2008; 19 Suppl 4: iv51-3
https://www.ncbi.nlm.nih.gov/pubmed/18519404
Hallek M: Chronic lymphocytic leukemia: 2017 update on diagnosis, risk
stratification, and treatment; Am J Hematol 2017; 92: 946–965
https://www.ncbi.nlm.nih.gov/pubmed/28782884
Jones JA, Mato AR, Wierda WG, et al.: Venetoclax for chronic lymphocytic
leukaemia progressing after ibrutinib: an interim analysis of a multicentre,
open-label, phase 2 trial; Lancet Oncol 2018; 19: 65–75
https://www.ncbi.nlm.nih.gov/pubmed/29246803
Kater AP, Seymour JF, Hillmen P, et al.: Fixed duration of Venetoclax-Rituximab
in relapsed/refractory chronic lymphocytic leukemia eradicates
minimal residual disease and prolongs survival: Post-treatment follow-up of
the MURANO Phase III study; J Clin Oncol 2019; 37: 269–277
https://www.ncbi.nlm.nih.gov/pubmed/30523712
Mato AR, Hill BT, Lamanna N, et al.: Optimal sequencing of ibrutinib,
idelalisib, and venetoclax in chronic lymphocytic leukemia: results from a
multicenter study of 683 patients; Ann Oncol 2017; 28: 1050–1056
https://www.ncbi.nlm.nih.gov/pubmed/28453705
Onkopedia Leitlinie CLL, 2017
http://www.oegho.at/onkopedia-leitlinien/haematologische-neoplasien/
chronische-lymphatische-leukaemie-cll.html
Potter DS & Letai A: To prime, or not to prime: that is the question; Cold
Spring Harb Symp Quant Biol 2016; 81: 131–140
https://www.ncbi.nlm.nih.gov/pubmed/27811212
Roberts, A.W. et al.: Substantial susceptibility of chronic lymphocytic
leukemia to BCL2 inhibition: results of a phase I study of navitoclax in
patients with relapsed or refractory disease; J Clin Oncol 2012; 30: 488-96
https://www.ncbi.nlm.nih.gov/pubmed/22184378
Roberts AW, Seymour JF, Brown JR, et al.: Targeting BCL2 with venetoclax in
relapsed chronic lymphocytic leukemia; N Engl J Med 2016; 374: 311–322
https://www.ncbi.nlm.nih.gov/pubmed/26639348
Roberts AW & Huang D: Targeting BCL2 with BH3 mimetics: basic science
and clinical application of venetoclax in chronic lymphocytic leukemia and
related B cell malignancies; Clin Pharmacol Ther 2017; 101: 89–98
https://www.ncbi.nlm.nih.gov/pubmed/27806433
Rossi D, Rasi S, Spina V, et al.: Integrated mutational and cytogenetic
analysis identifies new prognostic subgroups in chronic lymphocytic
leukemia; Blood 2013; 121:1403–1412
https://www.ncbi.nlm.nih.gov/pubmed/23243274
Seymour JF, Ma S, Brander DM, et al.: Venetoclax plus rituximab in relapsed
or refractory chronic lymphocytic leukaemia: a phase 1b study; Lancet
Oncol 2017; 18: 230–240
https://www.ncbi.nlm.nih.gov/pubmed/28089635
Seymour JF, Kipps T, Eichhorst B, et al.: Venetoclax-Rituximab in relapsed or
refractory chronic lymphocytic leukemia; N Engl J Med 2018; 378: 1107–1120
https://www.ncbi.nlm.nih.gov/pubmed/29562156
Souers AJ, Leverson JD, Boghaert ER, et al.: ABT-199, a potent and selective
BCL-2 inhibitor, achieves antitumor activity while sparing platelets; Nat
Med 2013; 19: 202–208
https://www.ncbi.nlm.nih.gov/pubmed/23291630
Stilgenbauer S, Eichhorst B, Schetelig J, et al.: Venetoclax in relapsed or
refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre,
open-label, phase 2 study; Lancet Oncol 2016; 17: 768–778
https://www.ncbi.nlm.nih.gov/pubmed/29715056
Stilgenbauer S, Eichhorst B, Schetelig J, et al.: Venetoclax for patients with
chronic lymphocytic leukemia with 17p deletion: Results from the full
population of a phase II pivotal trial; J Clin Oncol 2018; 36: 1973–1980
https://www.ncbi.nlm.nih.gov/pubmed/29715056
Thijssen R, Slinger E, Weller K, et al.: Resistance to ABT-199 induced by
microenvironmental signals in chronic lymphocytic leukemia can be
counteracted by CD20 antibodies or kinase inhibitors; Haematologica 2015;
100: e302-6
https://www.ncbi.nlm.nih.gov/pubmed/25957396
14 ArzneimittelPROFIL Venetoclax April 2019